Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

In the latest trading session, Novo Nordisk (NVO) closed at $87.37, marking a -1.51% move from the previous day.

Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note

Novo Nordisk's recent CagriSema study disappointed and led to a massive selloff as investor pessimism deepened. Eli Lilly stock's relative outperformance could strengthen its bullish case, but NVO isn't expected to surrender market leadership just yet. NVO has several opportunities to expand indications on its weight loss drugs and potentially further its TAM.

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.

Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.

Retail investors buy Novo dip after disappointing weight-loss drug data

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over this period.

Will Novo Nordisk (NVO) Stock Recover To $145 Levels?

Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.

NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Eli Lilly

In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Better Buy: Eli Lilly or Novo Nordisk?

Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company's potential following disappointing trial results for its CagriSema weight-loss drug.

Novo Nordisk shares rebound 8%: can European markets sustain the rally?

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.

Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark

Trials of semaglutide in patients with Alzheimer's and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health's analysts said

Novo Nordisk's 27% drop was market overreaction, analysts say

European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany Company Announcement 21/2024 (23.12.2024) Today, European Energy A/S has completed the sale of a 50 percent shareholding in the company owning German operational assets of 151.9 MW to Novo Holdings A/S. The wind farms are located in seven different federal states in Germany  and went into operation between 2002 and 2008.

European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany

AbbVie

Vertex Pharmaceuticals

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the agency said on Friday.

US FDA approves Novo Nordisk's bleeding disorder drug

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumbling as much as 24% at one point in premarket trading on Friday morning.

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.

Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher

Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.

Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.

Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.7% in a late-stage trial – lower than 25% it had originally expected.

Novo Nordisk stock just tanked 25%: here's what happened

Bad news for Novo Nordisk (NVO -17.77%) Friday was good news for Eli Lilly (LLY 4.88%) and Viking Therapeutics (VKTX 5.86%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug, CagriSema, and while objectively not bad, the results were less great than Novo was shooting for.

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

Novo Nordisk shares plummet after weight-loss drug's disappointing trial results

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch

Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's  weight loss drug  CagriSema missed expectations of a late-stage study.

Novo Nordisk Stock Eyes Worst Day, Week on Record

Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible dosing protocol led to fewer patients reaching the highest dose, impacting the overall efficacy results.

Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial

As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).

Novo Nordisk Stock: A Rare Buying Opportunity

Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.

News for Novo Nordisk Stock (NVO)